Almirall: shares rise on strong results; solid outlook
(CercleFinance.com) - Almirall, a biopharmaceutical company that is based in Barcelona, said it returned to growth in 2018 and has provided a solid outlook for 2019, sending its shares up nearly 3%.
Helped by its European psoriasis franchise, the drugmaker reported total revenues of 811 million euros for the past year, from 755.8 million euros in 2017, while its gross profit rose to 529.2 million euros, from 455.8 million euros in 2017.
Almirall - which acquired the US medical dermatology portfolio from Allergan - said revenues are expected to report low double-digit growth in 2019, based on constant exchange rates.
The group plans to pay a gross dividend of 0.203 euro per share, representing an increase of 7% from 2017, with a 40% payout of its net income.
Investors warmly welcomed this report, with the shares rising 2.9% at 14.9 euros this morning in Madrid.
Copyright (c) 2019 CercleFinance.com. All rights reserved.